Summary of use during lactation
No information is available on the clinical use of lurbinectedin during breastfeeding. Because lurbinectedin is about 99% bound to plasma proteins, the amount in milk is likely to be low. Most sources consider that mothers receiving antineoplastic therapy should not breastfeed, especially with alkylating agents such as lurbinectedin.[1] The manufacturer recommends not to breastfeed during treatment and for 2 weeks after the last dose. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[3]
Drug levels in milk and infant serum
Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.